Ganglioneuroma - An Overview

Introduction:

Ganglioneuroma is a kind of neurogenic tumor that may be detected by chance. The preferred therapy is surgical removal; however, the postoperative risks and consequences may exceed the advantages. For example, suppose a diagnosis of ganglioneuroma cannot be made before mass displacement. In that case, the objective of therapy should be to minimize the possibility of complications, even if partial resection can be done.

What Is Ganglioneuroma?

• Ganglioneuroma is the most prevalent solid extracranial malignancy in infancy and childhood. It is a peripheral neuroblastic tumor and comprises its histotypes.

• These neural crest tumors develop from the sympathetic ganglia or the adrenal medulla and exhibit a continuous spectrum of differentiation and neuronal development.

• The most frequent and deadly kind is ganglioneuroma which has a histologic pattern of numerous neuroblasts and sparse stroma.

• Ganglioneuroma is the less severe and less common variant. It is a stroma-predominant tumor with ganglion cells that are more or less developed.

• Neuroblasts, intermediate cells, and mitotic figures are not mature constituents of pure ganglioneuroma.

What Is the Classification of Ganglioneuroma?

The three main types of histotypes of ganglioneuroma are as follows:

1. Neuroblastoma (NB).

2. Ganglioneuroblastoma (GNB).

3. Ganglioneuroma (GN)

Ganglioneuroma has neuroblastic and stromal materials and is classified as

1. Nodular (with malignant potential and a poor prognosis).

2. Intermixed (stroma-rich) with a favorable prognosis.

What Is the Occurrence of Ganglioneuroma?

• Ganglioneuromas (GN) are uncommon benign neurogenic tumors that arise from neural crest sympathogonia.

• The most usually affected areas are the retroperitoneum, posterior mediastinum, and adrenal gland.

• There are not many ganglioneuromas (GN) in the cervical region; most are solitary, while occasionally, they can present many on one side of the neck.

• Multiple occurrences in the cervical region are exceedingly unusual.

• Ganglioneuroma (GN) often shows as a single, painless, slow-growing mass.

• Peripheral neuroblastic tumors (PNT), which include neuroblastomas (NB), ganglioneuromas (GN), and ganglioneuroblastomas (GNB), are uncommon, accounting for just 6 percent of pediatric cancers.

• Ganglioneuromas (GN) are the most differentiated and benign peripheral neuroblastic tumors (PNT), with the majority presenting as slow-growing, isolated lesions that may or may not affect surrounding tissues.

What Are the Signs and Symptoms of Ganglioneuroma?

People with ganglioneuromas (GN) release catecholamines which are secretory. Elevated catecholamines raise vanillylmandelic acid levels in the blood or urine, resulting in the following:

• Hypertension.

• Diarrhea.

• Sweating.

• Flushing.

• Renal acidosis.

What Are the Factors That Govern the Diagnosis of Ganglioneuroma?

• Ganglioneuroma almost invariably results from fetal or postnatal neuroblastoma or ganglioneuroblastoma (GNB) maturation.

• It is frequently asymptomatic and is commonly diagnosed by chance.

• However, in some instances, it can grow to a great size and displace or compress other organs.

• In contrast to neuroblastoma (NB), ganglioneuroma (GN) does not respond to chemotherapy, and surgical excision following a probable diagnosis based on imaging, catecholamine excretion or lack of amine uptake, has long been the treatment of choice.

• This contradicts the requirement for tissue diagnosis to implement procedures for central nervous system (CNS) malignancies.

How Is Ganglioneuroma Diagnosed?

Due to the scarcity of ganglioneuroma and the lack of distinct signs and symptoms, reaching a precise diagnosis before the pathological investigation is sometimes challenging. Computed tomography (CT scan) and magnetic resonance imaging (MRI) give essential information on the size, composition, location, and connection of the mass to nearby significant structures, which helps choose a surgical strategy. Ganglioneuroma (GN) is often characterized by a distinct oval or irregular mass with a hypodense appearance. Punctate and coarse calcifications are also found in a diffused scattered pattern, and contrast media administration might result in mild or moderate enhancement.

Magnetic resonance imaging (MRI) is superior to computed tomography (CT) in establishing intraspinal involvement; typical appearances of ganglioneuroma (GN) include

• Low intensity on T1-weighted images (T1WI).

• Conspicuous high intensity on T2-weighted images (T2WI).

• Gradually rising enhancement on dynamic magnetic resonance images.

Problems in Diagnosis:

• Big-size invasions of other body parts and metastases may offer unique challenges.

• Malignant transformation of a confirmed ganglioneuroma (GN) is probable.

• Imaging and biochemical indicators may not be sufficient to confirm the diagnosis.

What Are the Treatment Options for Ganglioneuroma?

Complete surgical excision is the treatment of choice, in which a transcervical or transoral approach may be employed depending on the tumor's location. The risks are mainly related to the intraoperative sacrifice of the neural structures and the vasculature associated with cancer. The prognosis of ganglioneuroma (GN) is usually good. Complete excision can be achieved, and the chances of recurrences are less. Symptoms of Horner’s syndrome are often detected following surgery, but these symptoms are usually entirely resolved within several months.

Even in situations with partial excision, another therapy such as chemotherapy or radiation is rarely necessary, however, if ganglioneuroma (GN) shows signs of immaturity.

Does Ganglioneuroma (GN) Need an Individual Approach to Treatment?

• Ganglioneuroma (GN) requires a personalized approach.

• Complete removal should be the goal of therapy without causing significant danger to the patient or nearby structures.

• When planning ganglioneuroma (GN) surgeries, an imaging-based estimate of the surgical risk variables staging should be considered.

• The surgeon should avoid complications as these cancers have a decent prognosis, and partial resection is justified.

• Nonoperative treatment of ganglioneuroma (GN) may be warranted in specific circumstances.

Differential Diagnosis of Ganglioneuroma

• Salivary gland tumors.

• Pleomorphic adenoma.

• Neurogenic tumors.

• Neurolemmoma.

• Fibrosarcomas.

• Neurofibroma.

• Fibrosarcomas.

• Soft tissue lesions.

• Malignant lymphomas.

• Rhabdomyosarcomas.

• Ganglioneuroblastomas are nerve tissue intermediate cancers. Removal is the sole therapy required.

• Gangliocytomas are tumors made up of mature neurons that can occur anywhere in the central nervous system.

• Gangliogliomas are slow-growing central nervous system tumors.

Complications of Ganglioneuroma

Early Complications:

1. Adhesion bowel blockage.

2. Urine retention.

3. Cerebrospinal fluid leak.

Late Consequences:

1. Mild scoliosis

2. Horner's syndrome.

3. Pneumothorax.

4. Chylothorax.

5. Arm discomfort.

What Is the Prognosis of Ganglioneuroma?

Most of the cases of ganglioneuroma are non-cancerous. The prognosis of this condition is usually good. In rare cases, it may become cancerous and may spread to other parts and can also occur after its removal.

Conclusion:

Ganglioneuroblastomas, ganglioneuromas, and neuroblastomas are all neurogenic tumors that behave differently biologically. Ganglioneuromas are hypothesized to develop from sympathetic ganglia, and their histology is distinct from that of other neurogenic tumors, including neuroblastoma. Despite these findings, a link between ganglioneuroma and neuroblastoma appears to exist. There is a description of a metachronous occurrence of ganglioneuroma and neuroblastoma, and the potential of malignant neuroblastoma maturing into a benign ganglioneuroma is strongly suggested. The cure for ganglioneuroma involves complete tumor removal, but the treatment for neuroblastoma depends on the stage of the disease and includes surgery, chemotherapy, and radiation.